Biosimilar interleukins market seen reaching $41.22 billion by 2030

9 hours ago
Biosimilar interleukins market seen reaching $41.22 billion by 2030
By AI, Created 18:30 UTC, Nov 20, 2026, AGP -

The Business Research Company says the global biosimilar interleukins market is on a steep growth path, rising from $7.52 billion in 2025 to a projected $41.22 billion by 2030. The expansion is being driven by higher autoimmune disease prevalence, patent expirations on branded interleukins and broader acceptance of lower-cost biosimilar therapies.

Why it matters: - Biosimilar interleukins could expand access to biologic treatments by lowering the cost barrier for patients with autoimmune, inflammatory and cancer-related conditions. - The market's projected growth signals more room for biosimilars in a segment long shaped by expensive branded biologics and limited patient access.

What happened: - The Business Research Company published its Biosimilar Interleukins Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the biosimilar interleukins market will grow from $7.52 billion in 2025 to $10.54 billion in 2026. - The report projects the market will reach $41.22 billion by 2030, implying a 40.6% CAGR. - North America held the largest market share in 2025.

The details: - The report ties recent growth to the high cost of original interleukin biologics, rising autoimmune and inflammatory disease rates, and more cases of rheumatoid arthritis and psoriasis. - Limited access to biologic therapies and growing awareness of biologics' role in immune system modulation also supported demand. - Future growth is expected to come from patent expirations on branded interleukins, expanding biosimilar pipelines in clinical development and greater physician acceptance. - Supportive government policies and rising demand for cost-effective biologics in oncology and immunology are also expected to help the market. - The report defines biosimilar interleukins as lab-produced versions of naturally occurring interleukins, which are signaling proteins secreted by white blood cells to regulate immune responses. - These biologics are used as immune response modifiers, including in cancer therapies and other immune-related treatments. - The report says wider adoption in autoimmune disease management, approvals for multiple therapeutic indications and stronger regulatory support are key developments ahead. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company offers a free sample of the report More information and the full report the full report.

Between the lines: - The fastest growth appears tied to demand for cheaper biologics in markets where autoimmune disease burden keeps rising. - The North America lead suggests the region's advanced care infrastructure and established biosimilar uptake are giving it a head start. - A projected 40.6% CAGR is unusually high for a healthcare submarket, which makes the forecast especially sensitive to approvals, pricing and physician adoption.

What's next: - The market's trajectory will likely depend on how quickly branded interleukin patents expire and how many biosimilars move from development into approval. - Broader regulatory support and physician adoption will be key to turning forecast demand into real commercial uptake. - North America is expected to remain the largest regional market if current adoption patterns hold.

The bottom line: - Biosimilar interleukins are moving from a niche opportunity to a major growth market, powered by disease burden, cost pressure and a more favorable biosimilar landscape.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Middle East Political Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Middle East Political Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.